Emyria Reveals “strong recruitment” for EMD-RX5 phase IIItrial
- Emyria (EMD) announces “strong recruitment” in a phase III clinical trial to facilitate its EMD-RX5 product in becoming an over-the-counter medicine
- The company has enrolled fifty patients and screened more than 100 in the trial, which is anticipated to end in July this year
- EMD-RX5 is an ultra-pure CBD capsule treatment designed to mitigate symptoms such as mild stress and anxiety for patients with chronic health conditions
- With no OTC treatment readily available in EMD’s target indication, the company believes it’s primed to “address a significant unmet need”
- EMD shares are trading at 17.5 cents at midday AEDT
